The DOI matches its Crossref record.
Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades
Abstract
BACKGROUND: Polo‐like kinase 1 (PLK1) is known to be one of the key players in the regulation of mitosis of both normal and malignant transformed cells. Moreover, several studies reported an overexpression of PLK1 in human malignancies compared to the corresponding tissue of origin. METHODS: In this study, expression of PLK1 was investigated by immunohistochemistry in 78 tissue specimens of prostate carcinoma and in adjacent normal prostate tissue as well as in benign prostate hyperplasia. PLK1 expression was semiquantitavely scored and subsequently correlated to clinicopathological parameters and patient prognosis. RESULTS: No significant PLK1 expression was observed in normal prostate glandular epithelium and stroma. Specimens of benign prostate hyperplasia were PLK1‐negative as well. In contrast, 52.6% of all prostate carcinomas showed strong expression of PLK1. High grade intraepithelial lesions, if present, stained almost invariably in the same manner as the respective invasive tumors. Expression of PLK1 correlated positively with Gleason grade (P = 0.011). No other significant correlations of PLK1 expression with either tumor stage, WHO tumor grade, preoperative PSA, age, or resection margins could be established. In an analysis for differences in PSA‐relapse‐free survival time, PLK1 expression was not a prognostic marker. CONCLUSIONS: These results demonstrate a high rate of PLK1‐positivity in prostate cancer which suggests involvement of PLK1 in tumorigenesis and progression in this tumor entity. Therefore, targeted strategies focussing on PLK1 inhibition might represent a promising new chemotherapeutic approach in prostate cancer. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting polo-like kinase 1 for cancer therapy
Strebhardt, K., & Ullrich, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1841 · Cited by 841
PLK1, A Potential Target for Cancer Therapy
Liu, Z., Sun, Q., & Wang, X. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.10.003 · Cited by 454
Current progress of siRNA/shRNA therapeutics in clinical trials
Burnett, J. C., Rossi, J. J., & Tiemann, K. (2011) · Biotechnology Journal · doi:10.1002/biot.201100054 · Cited by 444
Wu, J., Ivanov, A. I., Fisher, P. B., & Fu, Z. (2016) · eLife · doi:10.7554/elife.10734 · Cited by 117
Matthew, E. M., Hart, L. S., Astrinidis, A., Navaraj, A., Dolloff, N. G., Dicker, D. T., Henske, E. P., & El-Deiry, W. S. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10800 · Cited by 67
Metadata
- Authors
- Weichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K., Loening, S., Dietel, M., & Kristiansen, G.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2004-02-12
- Volume
- 60
- Issue
- 3
- Pages
- 240-245
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2041238848
- Cited by
- 188
- References
- 0
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. https://app.cochat.ai/papers/10.1002/pros.20050
- The paper
- Weichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K., Loening, S., Dietel, M., & Kristiansen, G. (2004). Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. The Prostate. https://doi.org/10.1002/pros.20050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.